Amgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety Read more about Amgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety
Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis Read more about Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis
Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins Read more about Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol Read more about New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session Read more about Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session
Amgen To Present At The Deutsche Bank 39th Annual Healthcare Conference Read more about Amgen To Present At The Deutsche Bank 39th Annual Healthcare Conference
Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion Read more about Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion
Amgen Announces Webcast of 2014 First Quarter Financial Results Read more about Amgen Announces Webcast of 2014 First Quarter Financial Results
Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma Read more about Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session Read more about Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session
